Turning the Tide on ATTR-CM: The Science and Evidence
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Turning the Tide on ATTR-CM: The Science and Evidence
-
ナレーター：
-
著者：
Join guest Dana Miller, Advanced HF Nurse Practitioner, to discuss the science and evidence to turn the tide on ATTR. Dana provides an overview of recent clinical trials and how an ATTR-CM diagnosis impacts rate of hospitalization, mortality and quality of life. Dana shares resources and recommendations to continue to learn more about the ever-evolving ATTR-CM treatment and management strategies.
Related PCNA Resources:
The Role of Artificial Intelligence in Cardiovascular Care: ATTR Case Study (CE Course)
Heart Failure and ATTR-CM: A Guide for Health Care Professionals
Hereditary Amyloidosis: What you need to know fact sheet
Related Episode Resources:
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance
Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study
Outcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias
Amyloidosis Research Consortium
Heart Failure Society of America (HFSA)
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.